Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

SAN DIEGO (June 12, 2013) Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms. Sickle cell anemia is a serious, painful and chronic illness that impedes blood flow and can lead to early death. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.

The phase II trial, funded by a $10.8 million grant from the National Institutes of Health, is testing an already existing drug called Lexiscan (regadenoson - Astellas Pharma US, Inc.), which is used for diagnosing heart disease. Researchers are exploring whether the drug's anti-inflammatory effects will significantly reduce the pain and blood flow disturbances of sickle cell anemia. A Phase I safety study was completed earlier this year. Recruitment is now under way for the trial's second phase to be conducted at treatment centers in eight major U.S. cities: Boston, Baltimore, Detroit, Chicago, Cincinnati, Milwaukee, Chapel Hill, and St. Louis.

"We are excited to begin the next phase of investigating Lexiscan's potential for reducing inflammation that contributes to the poor blood flow and serious complications of sickle cell disease," says La Jolla Institute scientist Joel Linden, Ph.D., a prominent researcher whose studies laid the groundwork for the trial. "Our phase I results were promising. Participants experienced no adverse reactions and our tests indicated that the drug significantly reduces inflammation. It is too early to tell whether this will translate into reduced pain and tissue damage. But we remain cautiously optimistic." The Phase I results were published as the cover article in th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... and Matthew Champion from the University of Notre Dame,s ... to directly detect bacterial protein secretion, which could provide ... The Champions point out that bacteria ... beyond their cell membrane in order to interact with ...
... by several orders of magnitude. The molecular mechanism by which ... and thus slows cell growth is described by biophysicists at ... the Online Early Edition of the journal PNAS . ... showed that Ras puts a phosphate chain under tension to ...
... MA A new article published today in ... evidence to suggest the current obesity epidemic in the ... high fructose corn syrup (HFCS). The commentary concludes ... research, there is overwhelming evidence showing HFCS is nutritionally ...
Cached Biology News:Notre Dame research could provide new insights into tuberculosis and other diseases 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 3Scientists conclude high fructose corn syrup should not be blamed for obesity 2
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... two studies in which researchers utilized Caris Molecular ... to identify potential therapeutic targets in patients with ... of the programmed cell death protein 1 (PD-1) ... June 1 at the 2015 American Society of ...
(Date:5/29/2015)... TRIANGLE PARK, N.C. , May 29, 2015 ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Jefferies 2015 Global Healthcare Conference ... The presentation and the immediately following Q&A session will take ... Time, and can be accessed via a live webcast on ...
(Date:5/29/2015)... Translation is frequently listed as one of the ... used in a way that is right for a company, ... product or service offering. , Here are some of ... on a company's bottom line: , 1.    Attract bigger audience. , ... can use, why not offer it globally? Nelson Mandela once ...
Breaking Biology Technology:Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Three Ways Translation Can Help Businesses Grow 2
... Pa., June 23 Environmental Tectonics Corporation (OTC Bulletin ... their BioMedical Division will be exhibiting at the upcoming ... an international, non-profit organization and is the primary source ... worldwide. , , The 2009 Annual UHMS meeting ...
... For NDA and to Complete Current Phase 3 Trial ... BETHESDA, Md., June 23 Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulatory consulting ... announced that it has received its first full-scale production ...
... Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ... involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin), showed ... survival rate against an inhaled lethal dose of anthrax. ... 16 mg/kg once-a-day (the human equivalent dose of 300 ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 2Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 3Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
Non-Protein Peroxidase Stabilizer , 1 L...
... Gelzyme is an agarose-digesting enzyme isolated ... simple carbohydrate bonds in agarose producing ... gel. The remaining carbohydrate molecules will ... DNA isolated with Gelzyme enzyme can ...
Biology Products: